开盘$531.53
昨收$542.50
当日区间$531.53 – $548.76
成交量1.27M
市值$138.71B
市盈率（TTM）35.2
股息率–
VRTX 相关新闻
匹配 Vertex Pharmaceuticals 或代码 VRTX 的头条新闻，按最新排序。
- News On Crinetics Pharmaceuticals Inc. (CRNX) Now Under VRTX
- Vertex Pharmaceuticals Names Jonathan Poole Chief Financial Officer, Effective Jan. 1 VRTX
- BofA Securities Maintains Vertex Pharmaceuticals(VRTX.US) With Buy Rating
- UBS Maintains Vertex Pharmaceuticals(VRTX.US) With Buy Rating, Raises Target Price to $615 正面
- Bernstein Maintains Vertex Pharmaceuticals(VRTX.US) With Buy Rating, Maintains Target Price $608
- A Quick Look at Today's Ratings for Vertex Pharmaceuticals(VRTX.US), With a Forecast Between $558 to $617
- A Quick Look at Today's Ratings for Vertex Pharmaceuticals(VRTX.US), With a Forecast Between $558 to $672
- Analysts Are Bullish on Top Healthcare Stocks: Vertex Pharmaceuticals (VRTX), Maze Therapeutics, Inc. (MAZE) 正面
- Morgan Stanley Maintains Vertex Pharmaceuticals(VRTX.US) With Buy Rating, Raises Target Price to $665 正面
- Analysts Offer Insights on Healthcare Companies: Vertex Pharmaceuticals (VRTX), Alumis Inc. (ALMS) and Medtronic (MDT)
- Citi Maintains Vertex Pharmaceuticals(VRTX.US) With Buy Rating, Maintains Target Price $585
- Scotiabank Maintains Vertex Pharmaceuticals(VRTX.US) With Buy Rating, Maintains Target Price $558
- Morgan Stanley Maintains Vertex Pharmaceuticals(VRTX.US) With Buy Rating, Maintains Target Price $665
- J.P. Morgan Maintains Vertex Pharmaceuticals(VRTX.US) With Buy Rating, Raises Target Price to $560 正面
- Maxim Group Maintains Vertex Pharmaceuticals(VRTX.US) With Buy Rating, Maintains Target Price $575
暂无评论——快来第一个聊聊 VRTX。
登录后参与讨论。